Effect of fenofibrate in the treatment of neonatal jaundice

The effect of fenofibrate on term neonatal hyperbilirubinemia admitted to hospital

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20201209049660N1

Enrollment

Registered

2020-12-24

Start date

2019-07-23

Completion date

Unknown

Last updated

2021-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neonatal jaundice. Neonatal jaundice from other and unspecified causes

Interventions

Intervention 1: Intervention group: 10 mg/kg fenofibrate (20 mg/ml syrup, Sobhan Darou, Iran) dissolved in 5 ml of distilled water plus phototherapy. Intervention 2: Control group: Only phototherapy.

Eligibility

Sex/Gender

All

Age

3 Days to 7 Days

Inclusion criteria

Inclusion criteria: Gestational age >= 37 weeks Weight >= 2500 g Age >=72 hours and =15 mg/dl and <=20 mg/dl

Exclusion criteria

Exclusion criteria: Hemolytic disease (ABO or Rh incompatibility) Direct hyperbilirubinemia >2 mg/dl G6PD deficiency Any specific disease including infections, systemic diseases, cephalohematoma, bowel obstruction, asphyxia, congenital anomalies, or chromosomal abnormalities History of phenobarbital intake before or after birth

Design outcomes

Primary

Measure	Time frame
Hospital length of stay. Timepoint: At the end of the study. Method of measurement: Patients' medical charts.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactBabak Gharaei Poor Abasabadi

Bandar Abbas Pediatric Hospital

babakgharaei59hums@gmail.com+98 76 3366 6242

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026